Startvac

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Escherichia coli J5 inactivated, Staphylococcus aureus (CP8) strain SP 140 inactivated, expressing slime-associated antigenic complex

Available from:

Laboratorios Hipra S.A.

ATC code:

QI02AB

INN (International Name):

adjuvanted inactivated vaccine for cattle against Staphylococcus aureus, coliforms and coagulase-negative staphylococci

Therapeutic group:

Stoka (krave i junice)

Therapeutic area:

Imunološki za bovide

Therapeutic indications:

Za stada imunizacija zdravih krava i junica u mliječnih pasmina goveda s ponavljajući маститов problema, kako smanjiti učestalost субклинических маститов i učestalosti i težini kliničkih znakova kliničkog мастита uzrokovane zlatni Staphylococcus, escherichia štapić i коагулазонегативные stafilokoki. Cijela imunizacijska shema potiče imunitet od otprilike prvog dana nakon prve injekcije do približno 78 dana nakon treće injekcije (ekvivalent za 130 dana nakon poroda).

Product summary:

Revision: 3

Authorization status:

odobren

Authorization date:

2009-02-11

Patient Information leaflet

                                15
B. UPUTA O VMP
16
UPUTA O VMP:
STARTVAC EMULZIJA ZA INJEKCIJU ZA GOVEDA.
1.
NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET I
NOSITELJA ODOBRENJA ZA PROIZVODNJU ODGOVORNOG ZA PUŠTANJE
SERIJE U PROMET, AKO JE RAZLIČITO
Nositelj odobrenja za stavljanje u promet i proizvođač odgovoran za
puštanje serije
u promet:
LABORATORIOS HIPRA, S.A.
Avda. la Selva, 135
17170- AMER (Girona)
SPAIN
2.
NAZIV VETERINARSKO MEDICINSKOG PROIZVODA
STARTVAC
emulzija za injekcije za goveda.
3.
KVALITATIVNI I KVANTITATIVNI SASTAV DJELATNE(IH) TVARI I DRUGIH
SASTOJAKA
Jedna doza (2 ml) sadrži:
_Escherichia coli _
(J5) inaktivirana
........................................................................
> 50 RED
60
*
_Staphylococcus aureus_
(CP8) soj SP 140 inaktiviran, koji izražava kompleks antigena
pridružen sluzi
(SAAC).......................................................................
........................................ > 50 RED
80
**
* RED
60
: djelotvorna doza u kunića, u 60% životinja (serološki nalaz).
** RED
80
: djelotvorna doza u kunića, u 80 % životinja (serološki nalaz).
parafin, tekući: 18,2 mg
benzilni alkohol: 21 mg
STARTVAC je homogena emulzija za injekciju boje slonovače.
4.
INDIKACIJE
Imunizacija stada zdravih krava i junica, u stadima mliječnih krava
gdje se opetovano javlja problem
mastitisa, da bi se umanjila učestalost subkliničkog mastitisa te
učestalost i težina kliničkih znakova
kliničkog mastitisa, koje uzrokuju
_Staphylococcus aureus_
, koliformne bakterije i koagulaza-negativni
stafilokoki.
Provedbom cjelovitog programa imunizacije potiče se imunost od oko
13-og dana nakon prve injekcije
do otprilike 78-og dana nakon treće injekcije.
5.
KONTRAINDIKACIJE
Nema.
6.
NUSPOJAVE
Vrlo rijetke nuspojave:
17
- Nakon primjene jedne doze cjepiva mogu se pojaviti lagane do
umjerene prolazne lokalne reakcije,
temeljem izvješća farmakovigilanciji nakon dobivanja odobrenja za
stavljanje u promet. U većini
slučajeva je to: oteklina (u prosjeku do 5 cm
2
), koja nestaje u roku od
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
DODATAK I
SAŽETAK OPISA SVOJSTAVA
2
1.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
STARTVAC emulzija za injekcije za goveda.
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Jedna doza (2 ml) sadrži:
DJELATNE TVARI:
_Escherichia coli _
J5 inaktivirana
..........................................................................
> 50 RED
60
*
_Staphylococcus aureus_
(CP8) soj SP 140 inaktiviran, koji izražava kompleks antigena
pridružen sluzi (SAAC) ..................
…………………………………………… > 50 RED
80
**
* RED
60
: djelotvorna doza u kunića, u 60% životinja (serološki nalaz).
** RED
80
: djelotvorna doza u kunića, u 80% životinja (serološki nalaz).
ADJUVANS:
Parafin,
tekući..............................................................................
18,2 mg
POMOĆNA TVAR:
Benzilni
alkohol……………..........................................................
21 mg
Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
3.
FARMACEUTSKI OBLIK
Emulzija za injekciju.
Homogena emulzija boje slonovače.
4.
KLINIČKE POJEDINOSTI
4.1
CILJNE VRSTE ŽIVOTINJA
Goveda (krave i junice).
4.2
INDIKACIJE ZA PRIMJENU, NAVESTI CILJNE VRSTE ŽIVOTINJA
Imunizacija stada zdravih krava i junica, u stadima mliječnih krava
gdje se opetovano javlja problem
mastitisa, da bi se umanjila učestalost subkliničkog mastitisa te
učestalost i težina kliničkih znakova
kliničkog mastitisa, koje uzrokuju
_Staphylococcus aureus_
, koliformne bakterije i koagulaza-negativni
stafilokoki.
Provedbom cjelovitog programa imunizacije potiče se imunost od oko
13-og dana nakon prve injekcije
do otprilike 78-og dana nakon treće injekcije.
4.3
KONTRAINDIKACIJE
Nema.
4.4
POSEBNA UPOZORENJA ZA SVAKU OD CILJNIH VRSTA ŽIVOTINJA
Treba imunizirati cijelo stado.
3
Imunizaciju treba smatrati jednim od sastavnih dijelova kompleksnog
programa kontrole mastitisa,
koji uključuje sve čimbenike važne za zdravo vime (npr. tehnika
mužnje, upravljanje zasušivanjem i
uzgojem, higijena, hranidba, nastambe, ležišta, udobnost krava,
kvalitet
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 07-05-2018
Summary of Product characteristics Summary of Product characteristics Bulgarian 07-05-2018
Public Assessment Report Public Assessment Report Bulgarian 17-02-2009
Patient Information leaflet Patient Information leaflet Spanish 07-05-2018
Public Assessment Report Public Assessment Report Spanish 17-02-2009
Patient Information leaflet Patient Information leaflet Czech 07-05-2018
Public Assessment Report Public Assessment Report Czech 17-02-2009
Patient Information leaflet Patient Information leaflet Danish 07-05-2018
Public Assessment Report Public Assessment Report Danish 17-02-2009
Patient Information leaflet Patient Information leaflet German 07-05-2018
Public Assessment Report Public Assessment Report German 17-02-2009
Patient Information leaflet Patient Information leaflet Estonian 07-05-2018
Public Assessment Report Public Assessment Report Estonian 17-02-2009
Patient Information leaflet Patient Information leaflet Greek 07-05-2018
Public Assessment Report Public Assessment Report Greek 17-02-2009
Patient Information leaflet Patient Information leaflet English 07-05-2018
Public Assessment Report Public Assessment Report English 17-02-2009
Patient Information leaflet Patient Information leaflet French 07-05-2018
Public Assessment Report Public Assessment Report French 17-02-2009
Patient Information leaflet Patient Information leaflet Italian 07-05-2018
Public Assessment Report Public Assessment Report Italian 17-02-2009
Patient Information leaflet Patient Information leaflet Latvian 07-05-2018
Public Assessment Report Public Assessment Report Latvian 17-02-2009
Patient Information leaflet Patient Information leaflet Lithuanian 07-05-2018
Summary of Product characteristics Summary of Product characteristics Lithuanian 07-05-2018
Public Assessment Report Public Assessment Report Lithuanian 17-02-2009
Patient Information leaflet Patient Information leaflet Hungarian 07-05-2018
Summary of Product characteristics Summary of Product characteristics Hungarian 07-05-2018
Public Assessment Report Public Assessment Report Hungarian 17-02-2009
Patient Information leaflet Patient Information leaflet Maltese 07-05-2018
Public Assessment Report Public Assessment Report Maltese 17-02-2009
Patient Information leaflet Patient Information leaflet Dutch 07-05-2018
Public Assessment Report Public Assessment Report Dutch 17-02-2009
Patient Information leaflet Patient Information leaflet Polish 07-05-2018
Public Assessment Report Public Assessment Report Polish 17-02-2009
Patient Information leaflet Patient Information leaflet Portuguese 07-05-2018
Summary of Product characteristics Summary of Product characteristics Portuguese 07-05-2018
Public Assessment Report Public Assessment Report Portuguese 17-02-2009
Patient Information leaflet Patient Information leaflet Romanian 07-05-2018
Public Assessment Report Public Assessment Report Romanian 17-02-2009
Patient Information leaflet Patient Information leaflet Slovak 07-05-2018
Public Assessment Report Public Assessment Report Slovak 17-02-2009
Patient Information leaflet Patient Information leaflet Slovenian 07-05-2018
Summary of Product characteristics Summary of Product characteristics Slovenian 07-05-2018
Public Assessment Report Public Assessment Report Slovenian 17-02-2009
Patient Information leaflet Patient Information leaflet Finnish 07-05-2018
Public Assessment Report Public Assessment Report Finnish 17-02-2009
Patient Information leaflet Patient Information leaflet Swedish 07-05-2018
Public Assessment Report Public Assessment Report Swedish 17-02-2009
Patient Information leaflet Patient Information leaflet Norwegian 07-05-2018
Summary of Product characteristics Summary of Product characteristics Norwegian 07-05-2018
Patient Information leaflet Patient Information leaflet Icelandic 07-05-2018
Summary of Product characteristics Summary of Product characteristics Icelandic 07-05-2018

View documents history